Durability of Humoral Responses after the Second Dose of mRNA BNT162b2 Vaccine in Residents of a Long Term Care Facility
Residents of long-term care facilities (LTCFs) have been dramatically hit by the COVID-19 pandemic on a global scale as older age and comorbidities pose an increased risk of severe disease and death. The aim of the study was to assess the quantity and durability of specific antibody responses to SAR...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/3/446 |
| _version_ | 1797441167021834240 |
|---|---|
| author | Alessia Lai Barbara Caimi Marco Franzetti Annalisa Bergna Rossella Velleca Antonella Gatti Pier Luigi Rossi Marco D’Orso Fabrizio Pregliasco Claudia Balotta Giuseppe Calicchio |
| author_facet | Alessia Lai Barbara Caimi Marco Franzetti Annalisa Bergna Rossella Velleca Antonella Gatti Pier Luigi Rossi Marco D’Orso Fabrizio Pregliasco Claudia Balotta Giuseppe Calicchio |
| author_sort | Alessia Lai |
| collection | DOAJ |
| description | Residents of long-term care facilities (LTCFs) have been dramatically hit by the COVID-19 pandemic on a global scale as older age and comorbidities pose an increased risk of severe disease and death. The aim of the study was to assess the quantity and durability of specific antibody responses to SARS-CoV-2 after the first cycle (two doses) of BNT162b2 vaccine. To achieve this, SARS-CoV-2 Spike-specific IgG (S-IgG) titers was evaluated in 432 residents of the largest Italian LTCF at months 2 and 6 after vaccination. By stratifying levels of humoral responses as high, medium, low and null, we did not find any difference when comparing the two time points; however, the median levels of antibodies halved overtime. As positive nucleocapsid serology was associated with a reduced risk of a suboptimal response at both time points, we conducted separate analyses accordingly. In subjects with positive serology, the median level of anti-S IgG slightly increased at the second time point, while a significant reduction was observed in patients without previous exposure to the virus. At month 6, diabetes alone was associated with an increased risk of impaired response. Our data provide additional insights into the longitudinal dynamics of the immune response to BNT162b2 vaccination in the elderly, highlighting the need for SARS-CoV-2 antibody monitoring following third-dose administration. |
| first_indexed | 2024-03-09T12:19:05Z |
| format | Article |
| id | doaj.art-a6054ab49c9d4202a55ae66ff28cce4d |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T12:19:05Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-a6054ab49c9d4202a55ae66ff28cce4d2023-11-30T22:43:03ZengMDPI AGVaccines2076-393X2022-03-0110344610.3390/vaccines10030446Durability of Humoral Responses after the Second Dose of mRNA BNT162b2 Vaccine in Residents of a Long Term Care FacilityAlessia Lai0Barbara Caimi1Marco Franzetti2Annalisa Bergna3Rossella Velleca4Antonella Gatti5Pier Luigi Rossi6Marco D’Orso7Fabrizio Pregliasco8Claudia Balotta9Giuseppe Calicchio10Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, 20157 Milan, ItalyAzienda Servizi alla Persona, Istituti Milanesi Martinitt e Stelline e Pio Albergo Trivulzio, 20146 Milan, ItalyInfectious Diseases Unit, Legnano General Hospital, ASST Ovest Milanese, 20025 Legnano, ItalyDepartment of Biomedical and Clinical Sciences L. Sacco, University of Milan, 20157 Milan, ItalyAzienda Servizi alla Persona, Istituti Milanesi Martinitt e Stelline e Pio Albergo Trivulzio, 20146 Milan, ItalyAzienda Servizi alla Persona, Istituti Milanesi Martinitt e Stelline e Pio Albergo Trivulzio, 20146 Milan, ItalyAzienda Servizi alla Persona, Istituti Milanesi Martinitt e Stelline e Pio Albergo Trivulzio, 20146 Milan, ItalyDepartment of Medicine and Surgery, University of Milan-Bicocca, 20900 Monza, ItalyDepartment of Biomedical Sciences, IRCCS Istituto Ortopedico Galeazzi, University of Milan, 20161 Milan, ItalyDepartment of Biomedical and Clinical Sciences L. Sacco, University of Milan, 20157 Milan, ItalyAzienda Servizi alla Persona, Istituti Milanesi Martinitt e Stelline e Pio Albergo Trivulzio, 20146 Milan, ItalyResidents of long-term care facilities (LTCFs) have been dramatically hit by the COVID-19 pandemic on a global scale as older age and comorbidities pose an increased risk of severe disease and death. The aim of the study was to assess the quantity and durability of specific antibody responses to SARS-CoV-2 after the first cycle (two doses) of BNT162b2 vaccine. To achieve this, SARS-CoV-2 Spike-specific IgG (S-IgG) titers was evaluated in 432 residents of the largest Italian LTCF at months 2 and 6 after vaccination. By stratifying levels of humoral responses as high, medium, low and null, we did not find any difference when comparing the two time points; however, the median levels of antibodies halved overtime. As positive nucleocapsid serology was associated with a reduced risk of a suboptimal response at both time points, we conducted separate analyses accordingly. In subjects with positive serology, the median level of anti-S IgG slightly increased at the second time point, while a significant reduction was observed in patients without previous exposure to the virus. At month 6, diabetes alone was associated with an increased risk of impaired response. Our data provide additional insights into the longitudinal dynamics of the immune response to BNT162b2 vaccination in the elderly, highlighting the need for SARS-CoV-2 antibody monitoring following third-dose administration.https://www.mdpi.com/2076-393X/10/3/446long-term care facilitieshumoral responsesnucleocapsid serologyCOVID-19vaccines |
| spellingShingle | Alessia Lai Barbara Caimi Marco Franzetti Annalisa Bergna Rossella Velleca Antonella Gatti Pier Luigi Rossi Marco D’Orso Fabrizio Pregliasco Claudia Balotta Giuseppe Calicchio Durability of Humoral Responses after the Second Dose of mRNA BNT162b2 Vaccine in Residents of a Long Term Care Facility Vaccines long-term care facilities humoral responses nucleocapsid serology COVID-19 vaccines |
| title | Durability of Humoral Responses after the Second Dose of mRNA BNT162b2 Vaccine in Residents of a Long Term Care Facility |
| title_full | Durability of Humoral Responses after the Second Dose of mRNA BNT162b2 Vaccine in Residents of a Long Term Care Facility |
| title_fullStr | Durability of Humoral Responses after the Second Dose of mRNA BNT162b2 Vaccine in Residents of a Long Term Care Facility |
| title_full_unstemmed | Durability of Humoral Responses after the Second Dose of mRNA BNT162b2 Vaccine in Residents of a Long Term Care Facility |
| title_short | Durability of Humoral Responses after the Second Dose of mRNA BNT162b2 Vaccine in Residents of a Long Term Care Facility |
| title_sort | durability of humoral responses after the second dose of mrna bnt162b2 vaccine in residents of a long term care facility |
| topic | long-term care facilities humoral responses nucleocapsid serology COVID-19 vaccines |
| url | https://www.mdpi.com/2076-393X/10/3/446 |
| work_keys_str_mv | AT alessialai durabilityofhumoralresponsesaftertheseconddoseofmrnabnt162b2vaccineinresidentsofalongtermcarefacility AT barbaracaimi durabilityofhumoralresponsesaftertheseconddoseofmrnabnt162b2vaccineinresidentsofalongtermcarefacility AT marcofranzetti durabilityofhumoralresponsesaftertheseconddoseofmrnabnt162b2vaccineinresidentsofalongtermcarefacility AT annalisabergna durabilityofhumoralresponsesaftertheseconddoseofmrnabnt162b2vaccineinresidentsofalongtermcarefacility AT rossellavelleca durabilityofhumoralresponsesaftertheseconddoseofmrnabnt162b2vaccineinresidentsofalongtermcarefacility AT antonellagatti durabilityofhumoralresponsesaftertheseconddoseofmrnabnt162b2vaccineinresidentsofalongtermcarefacility AT pierluigirossi durabilityofhumoralresponsesaftertheseconddoseofmrnabnt162b2vaccineinresidentsofalongtermcarefacility AT marcodorso durabilityofhumoralresponsesaftertheseconddoseofmrnabnt162b2vaccineinresidentsofalongtermcarefacility AT fabriziopregliasco durabilityofhumoralresponsesaftertheseconddoseofmrnabnt162b2vaccineinresidentsofalongtermcarefacility AT claudiabalotta durabilityofhumoralresponsesaftertheseconddoseofmrnabnt162b2vaccineinresidentsofalongtermcarefacility AT giuseppecalicchio durabilityofhumoralresponsesaftertheseconddoseofmrnabnt162b2vaccineinresidentsofalongtermcarefacility |